476TiP Phase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

Kinase Inhibitor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(16)30299-4 ◽

2016 ◽

Vol 11 (4) ◽

pp. S139 ◽

Cited By ~ 11

Author(s):

K. Park ◽

J.-Y. Han ◽

D.-W. Kim ◽

L.A. Bazhenova ◽

S.-H. Ou ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer

Drugs of Today ◽

10.1358/dot.2019.55.4.2965337 ◽

2019 ◽

Vol 55 (4) ◽

pp. 231 ◽

Cited By ~ 4

Author(s):

T. Nagano ◽

M. Tachihara ◽

Y. Nishimura

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Combination effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and individual chemotherapeutics in non-small cell lung cancer (NSCLC) cells with and without sensitizing-EGFR mutations.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e18062 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e18062-e18062

Author(s):

C. Tsai ◽

K. Chang ◽

C. Chiu ◽

S. Hsiao

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

Epidermal Growth ◽

Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts

European Journal of Cancer ◽

10.1016/s0959-8049(02)80848-6 ◽

2002 ◽

Vol 38 ◽

pp. S62

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Platinum Based Chemotherapy ◽

Epidermal Growth ◽

PCN133 ECONOMIC EVALUATION OF EPIDERMAL GROWTH FACTOR RECEPTOR - TYROSINE KINASE INHIBITOR (EGFR-TKI) DRUGS IN NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT: A SYSTEMATIC REVIEW OF RECENT STUDIES

Value in Health ◽

10.1016/j.jval.2020.04.1622 ◽

2020 ◽

Vol 23 ◽

pp. S46

Author(s):

M. Karim ◽

A.K. Nabil ◽

N. Khodakarami ◽

H.C. Kum ◽

M.J. Foster ◽

...

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer

Bioengineered ◽

10.1080/21655979.2021.2009969 ◽

2021 ◽

Author(s):

Xuan Zhou ◽

Ting Jin ◽

Likun Wang ◽

Erlin Zhao ◽

Xuyang Xiao

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Oxide Nanoparticles ◽

Targeted Drugs ◽

Small Cell Lung ◽

Epidermal Growth

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients

European Journal of Cancer ◽

10.1016/j.ejca.2019.05.032 ◽

2019 ◽

Vol 117 ◽

pp. 107-115 ◽

Cited By ~ 7

Author(s):

Zong-Han Yao ◽

Wei-Yu Liao ◽

Chao-Chi Ho ◽

Kuan-Yu Chen ◽

Jin-Yuan Shih ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Epidermal Growth ◽

Inhibitor Treatment

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000263712.61697.69 ◽

2007 ◽

Vol 2 (4) ◽

pp. 299-305 ◽

Cited By ~ 44

Author(s):

Shirish M. Gadgeel ◽

John C. Ruckdeschel ◽

Elisabeth I. Heath ◽

Lance K. Heilbrun ◽

Raghu Venkatramanamoorthy ◽

...

Keyword(s):

Kinase Inhibitor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Platinum Refractory ◽

Epidermal Growth ◽

Cox 2 ◽

The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)

Annals of Oncology ◽

10.1093/annonc/mdy292.046 ◽

2018 ◽

Vol 29 ◽

pp. viii514

Author(s):

K. Usui ◽

T. Yokoyama ◽

A. Kisohara ◽

Y. Mori ◽

Y. Takeda ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Tki Treatment ◽

Egfr Mutant ◽

125P Association of tumour CD4 positive lymphocytes with prognosis in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor

Annals of Oncology ◽

10.1016/j.annonc.2020.08.246 ◽

2020 ◽

Vol 31 ◽

pp. S290

Author(s):

Y-J. Zhu ◽

H-B. Zhang ◽

X-S. Chang ◽

Z-Z. Xiao ◽

L-R. Liu ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Epidermal Growth